These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23856973)

  • 1. Therapeutic effects of thalidomide in hematologic disorders: a review.
    Xu M; Hou Y; Sheng L; Peng J
    Front Med; 2013 Sep; 7(3):290-300. PubMed ID: 23856973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thalidomide: mechanisms of action and new insights in hematology].
    Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
    Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [IMiDs in hematology].
    Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
    Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of thalidomide in the treatment of cancer.
    Rajkumar SV
    Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lenalidomide in hematological malignancies---review].
    Jin X; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide in cancer medicine.
    Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA
    Ann Oncol; 2004 Aug; 15(8):1151-60. PubMed ID: 15277253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy in hematologic malignancies.
    Moehler TM; Hillengass J; Goldschmidt H; Ho AD
    Curr Pharm Des; 2004; 10(11):1221-34. PubMed ID: 15078137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in the treatment of plasma cell malignancies.
    Rajkumar SV; Kyle RA
    J Clin Oncol; 2001 Aug; 19(16):3593-5. PubMed ID: 11504740
    [No Abstract]   [Full Text] [Related]  

  • 9. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.
    Ribatti D; Vacca A
    Leukemia; 2005 Sep; 19(9):1525-31. PubMed ID: 15973447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trials investigate first-line thalidomide in multiple myeloma.
    Owen OG
    Lancet Oncol; 2005 Jan; 6(1):6. PubMed ID: 15672486
    [No Abstract]   [Full Text] [Related]  

  • 12. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
    Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK
    Leuk Lymphoma; 2003 Jul; 44(7):1147-9. PubMed ID: 12916866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.
    Desikan RK; Jagannath S
    Semin Oncol; 2001 Dec; 28(6):593-6. PubMed ID: 11740815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current role of thalidomide in cancer treatment.
    Thomas DA; Kantarjian HM
    Curr Opin Oncol; 2000 Nov; 12(6):564-73. PubMed ID: 11085456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy].
    Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Mödder U
    Radiologe; 2002 Mar; 42(3):222-30. PubMed ID: 11963240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide in multiple myeloma.
    Rajkumar SV
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
    Breitkreutz I; Anderson KC
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
    Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G
    Ann Oncol; 2001 Jul; 12(7):987-90. PubMed ID: 11521807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
    Rajkumar SV
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):17-22. PubMed ID: 15015892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematological cancer: a step before the next leap?
    Vij R
    Nat Rev Clin Oncol; 2013 Nov; 10(11):610-2. PubMed ID: 24101121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.